survodutide vs semaglutide What Is Survodutide? GLP-1/Glucagon Agonist New Developments in Pharmacological Treatment

Who Is Not a Good Candidate

Wegovy for weight loss is injected just under the skin into areas with adequate fatty tissue

Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population

At our practice in Jupiter GHK-Cu Peptide Therapy is available in oral and topical form

The policy options presented are NOT recommendations or official statements of HHS policy positions

D., Hossain M